Clinical trials: Mental
Depression, Anxiety
Focused Ultrasound for Behavioral Health
This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201…
- Conditions
- Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
- Trial name
- VANTUS (NCT07851038)
- Testing
- ATTN201 head-worn focused ultrasound
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Attune Neurosciences Inc
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in psychiatrically stable schizophrenia patients.
- Trial name
- NCT01952132
- Testing
- OMS643762
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Omeros Corporation
Schizophrenia
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.
- Trial name
- NCT00892021
- Testing
- NSA-789
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Schizoaffective Disorder
Sustainable Early Episode Clinic Study (SEEC)
The purpose of this study is to describe relapse rates among participants receiving services in the SEEC program high intensity resource use.
- Trial name
- SEEC (NCT03571685)
- Testing
- Sustainable Early Episode Clinic Model of Care
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Janssen Scientific Affairs, LLC
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Alzheimer's Disease
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease
Purpose: The purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd.
- Trial name
- NCT02253043
- Testing
- Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192906
- Testing
- bitopertin [RO4917838]
- Where
- 113 sites in United States, Brazil and 12 more
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia
- Trial name
- NCT00316238
- Testing
- olanzapine-RAIM
- Where
- 15 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Borderline Personality Disorder
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients
In patients with schizophrenia, 'atypical' antipsychotics such as clozapine may be effective in the treatment of psychosis. In patients with borderline personality disorder (BPD), as far as the investigators know, no well…
- Trial name
- NCT00254748
- Testing
- Quetiapine fumarate
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Eating Disorders
The Use of Smart Devices in Capturing Digital Biomarkers in Eating Disorders
This study aims to explore how smart devices can be used to monitor the health of individuals with eating disorders. Eating disorders are serious mental health conditions that impact both mental and physical health.
- Trial name
- NCT06544226
- Testing
- UH100
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Univa Health
Schizophrenia
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.
- Trial name
- NCT02202226
- Testing
- Lu AF35700
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Autism
Synthetic Human Secretin in Children With Autism
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
- Trial name
- NCT00036244
- Testing
- RG1068 (Synthetic Human Secretin)
- Where
- 15 sites in United States
- Sponsor
- Repligen Corporation
Sexual Dysfunction, Male Erectile Dysfunction
Levitra (Vardenafil, BAY38-9456) Partner Satisfaction Study II
This trial is to provide additional important information on the impact of the treatment of the man its ED with vardenafil on partnership.
- Trial name
- NCT00377793
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Where
- 47 sites in Belgium, France and 5 more
- Volunteers
- 352 people
- Sponsor
- Bayer
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Brain Concussion, Mild Cognitive Impairment
Development of a Neurocognitive Screening Test
This research study will evaluate a standalone software application and is designed to standardize and validate new neurocognitive screening testing for children aged 6 through 11, and adolescents and adults ages 12 through 75.
- Trial name
- NCT02597504
- Testing
- Pen and paper neuropsychological test, Quick Test
- Where
- 4 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- ImPACT Applications, Inc.
Cannabis Intoxication
Cannabis Impairment Detection Device Study
The goal of this study is to develop a cannabis impairment detection device in adult cannabis users. The main question[s] it aims to answer are: Is the investigational device accurate and reliable at detecting cannabis…
- Trial name
- NCT07122349
- Testing
- Cannabis Impairment Test
- Where
- Canada
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Gaize
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.